Iron-rich noodles and vitamin-rich beverages are some products launched by segment majors
India was the flavour of the year, at least in the FMCG sector, as multinationals hiked stakes in their subsidiaries lured by long term potential of the country, while homegrown executives made their way to top hierarchy of global firms in 2013.
Dilip Shanghvi founded Sun Pharma in 1983.
Sensex rises, Nifty ends at record high; RIL shares rally.
Advertising taglines such as 'Bright in studies, bright in sports' attempted to drive home the message that Bournvita, a chocolate drink, could build a child's mental and physical faculties.
The investigation against HUL was initiated on the basis of an anonymous complaint. It alleged 'profiteering' of around Rs 535 crore between November 15, 2017, and February 28, 2018.
Softening rural consumption and the likelihood of weak corporate earnings in the March quarter saw investors dump stocks.
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
NPPA suggests expanding the list of essential medicines whose prices are controlled
It also marks the culmination of the revamp exercise that the brand undertook 18 months back, spearheaded by Nellaiappan Thiruambalam, who was appointed as director and CEO of the personal care and foods division in April 2013.
Growth in cities has lagged villages as consumers troubled by persistently high inflation have cut spending in the past two years.
@015 may be a good year for FMCG firms.
Sensex rises, Nifty holds 8,900; FMCG, Pharma shares lead.
Markets rebound with financials leading the gains on hopes of a peaceful solution to the turmoil in Ukraine
The benchmark BSE Sensex ended down 2.23 per cent. The Bank Nifty fell 3.59 per cent.
The oralcare major has kept its ears firmly to the ground, pushing products into the hinterland and is holding fort in urban India with innovation for continued volume growth.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
FIIs pump in Rs 2,075 crore in past three trading sessions.
If you are not happy with the price offered at buybacks, you could be in for a long haul.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances